

Onabotulinum toxin-A can safely improve sleep bruxism

18 January 2018



Allergan Pharmaceuticals funded the study.

More information: <u>Abstract</u> <u>Full Text</u>

Copyright © 2018 <u>HealthDay</u>. All rights reserved.

(HealthDay)—Onabotulinum toxin-A (BoNT-A) injections can improve sleep bruxism, according to a study published online Jan. 17 in *Neurology*.

William G. Ondo, M.D., from the Methodist Neurological Institute in Houston, and colleagues recruited 31 patients aged 18 to 85 years with clinically diagnosed sleep bruxism confirmed by polysomnography. Twenty-three patients were randomized to either BoNT-A injection (13 patients) or placebo (10 <u>patients</u>; nine completed the study). Participants were assessed at four to eight weeks after the initial treatment visit.

The researchers found that clinical global impression (P

"BoNT-A effectively and safely improved sleep <u>bruxism</u> in this placebo-controlled pilot trial," the authors write. "A large multicenter trial is needed to confirm these encouraging data."

Two authors disclosed financial ties to Allergan;



APA citation: Onabotulinum toxin-A can safely improve sleep bruxism (2018, January 18) retrieved 14 September 2022 from <u>https://medicalxpress.com/news/2018-01-onabotulinum-toxin-a-safely-bruxism.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.